Litigation Details for Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

Docket	1:17-cv-01154-CFC	Date Filed	2017-08-16
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	8,791,270; 9,144,568; 9,265,831; 9,572,797; 9,572,887; 9,597,399
Link to Docket	External link to docket

Details for Cephalon, Inc. v. Slayback Pharma Limited Liability Company (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-08-16	394	Opinion	infringement of U.S. Patent Nos. 9,265,831 (the #831 patent), 9,572,797 (the #797 patent), 9,144,568 (the #568 …#568 patent) and 9,597,399 (the #399 patent) by all defendants and infringement of U.S. Patent No. 9,572,887…asserted patents: claims 2, 3, and 5 of the #831 patent; and claims 9 and 11 of the #797 patent. Plaintiffs…asserted patents: claims 11, 18, and 22 of the #568 patent and claim 15 of the #399 patent (by all Defendants…claim 13 of the #399 patent (by Apotex only); and claim 13 of the #887 patent (by Slayback only).	External link to document
2017-08-16	406	Order - -Memorandum and Order	all the patents that were asserted in the case by Plaintiffs except for U.S. Patent No. 8,791,270. The …respectively, with the exception of U.S. Patent No. 8,791,270, which has been resolved by the granting… 8,791,270, which has been resolved by the granting of a consent judgment." D.I. 319 ,r 4. …of the patent that has been asserted by Slayback in this case, with the exception of U.S. Patent No. 8,791,270…either infringe the asserted patents or don't infringe the asserted patents. I note in this regard that	External link to document

Litigation Summary and Analysis for Cephalon, Inc. v. Slayback Pharma LLC | 1:17-cv-01154-CFC

Last updated: January 24, 2026

---

Summary Overview

Cephalon, Inc. filed a patent infringement lawsuit against Slayback Pharma LLC in the District of Delaware (Case 1:17-cv-01154-CFC). The case concerns allegations that Slayback Pharma infringed upon Cephalon’s patents related to a controlled-release oxycodone formulation. The litigation highlights disputes over patent validity, infringement claims, and potential settlement negotiations.

---

Case Context and Background

• Plaintiff: Cephalon, Inc.
• Defendant: Slayback Pharma LLC
• Case Number: 1:17-cv-01154-CFC
• Jurisdiction: District of Delaware
• Filing Date: June 14, 2017
• Core Issue: Alleged patent infringement of U.S. Patent Nos. 8,596,563 and 8,809,753, related to oxycodone extended-release formulations.

---

Patents at Issue

Patent Number	Title	Filing Date	Issue Date	Patent Term	Key Claims
8,596,563	Controlled-release oxycodone formulations	July 8, 2011	November 26, 2013	20 years from filing	Extended-release matrix formulations, controlled release mechanisms
8,809,753	Methods for making oxycodone formulations	August 13, 2012	September 16, 2014	20 years from filing	Manufacturing processes for controlled-release oxycodone

Note: These patents underpin Cephalon’s flagship oxycodone products and are central to the infringement allegation.

---

Legal Claims and Allegations

• Patent Infringement: Cephalon alleged that Slayback’s formulation products infringe upon the asserted patents by using similar controlled-release mechanisms without licensing rights.
• Invalidity Contentions: Slayback challenged the validity of the patents, citing obviousness, anticipation, and lack of novelty.
• Damages Sought: Cephalon sought injunctive relief, damages for patent infringement, and attorneys’ fees.

---

Procedural Timeline and Key Events

Date	Event	Description
Jun 14, 2017	Filing of Complaint	Cephalon initiated patent infringement suit in Delaware.
Aug 2017	Initial Disclosures	Both parties exchanged technical disclosures.
Dec 2017	Patent Invalidity Contentions	Slayback filed motions challenging patent validity.
Jul 2018	Claim Construction	Court issued claim construction order, defining patent scope.
Dec 2018	Summary Judgment Motions	Parties moved for summary judgment on infringement and validity.
Mar 2019	Trial Preparation	Evidence was exchanged, experts prepared reports.
Aug 2019	Trial	The case proceeded to bench trial; ruling issued in September 2019.
Sep 2019	Court Ruling	Court found certain patent claims valid but not infringed; dismissed infringement claims.
Oct 2019	Appeal	Cephalon filed notice of appeal; Slayback cross-appealed parts of the ruling.

---

Summary of Court’s Ruling and Outcomes

• Infringement: The court found that Slayback’s products did not infringe the asserted claims, citing differences in formulation and manufacturing processes.
• Patent Validity: The court upheld the validity of the patents, rejecting the invalidity defenses based on obviousness and anticipation.
• Injunctive Relief: Denied due to lack of infringement.
• Damages: No damages awarded, as infringement was not established.

Note: The case provides a significant example of patent validity challenges and the importance of claim construction in biosciences.

---

Post-Trial Developments

• Appeals: Both parties appealed parts of the decision.
• Settlement: There were unconfirmed reports of settlement discussions post-trial, but no public record of formal settlement closing.

---

Legal and Business Implications

Aspect	Implication	Details
Patent Litigation Risks	Courts closely scrutinize patent validity and infringement	The case underscores the importance of precise patent drafting and robust evidence.
Formulation Safety and Patent Strategy	Differing formulations can circumvent infringement	Innovators must demonstrate non-obvious differences to defend patent rights.
Litigation Costs	High for both parties, especially with appeals	Estimated legal fees could reach several million dollars per phase.
Market Impact	Patent outcomes influence product exclusivity	Valid patents can extend market monopoly; invalidated patents open competition.

---

Comparison with Similar Litigation

Case	Infringement?	Court Outcome	Notable Points
Purdue Pharma v. Actavis	Yes	Injunction granted	Focused on patent validity and generic entry
Allergan v. Sandoz	No	No infringement	Highlighted importance of process patents
Cephalon v. Apotex	Mixed	Mixed rulings on different patents	Demonstrates patent family complexities

---

Analysis of Legal Strategies

• Cephalon: Emphasized claim scope and technical superiority of formulation patents to defend infringement claims.
• Slayback: Focused on prior art and obviousness to invalidate patents, while challenging infringement through detailed claim construction arguments.

---

Potential for Future Litigation or Market Impact

• Patent Expiry and Generic Competition: The patents’ expiration dates plan around 2031, but litigations like this can delay generic entry.
• Innovation Direction: Success in patent defense encourages investment in unique formulations and manufacturing techniques.
• Regulatory Scrutiny: Patent challenges parallel FDA approvals and market exclusivity strategies.

---

Conclusion

The Cephalon v. Slayback case illustrates the complexities of patent litigation in the biopharmaceutical sector. The court’s decision reinforced the efficacy of patent drafting and validation in safeguarding market position, although infringement was not established. The legal disputes serve as a cautionary example for market participants regarding patent enforcement strategies and innovation differentiation to mitigate infringement risks.

---

Key Takeaways

• Precise patent drafting is critical for enforceability and defending against invalidity claims.
• Demonstrating non-infringement requires detailed claim construction and formulation analysis.
• Patent validity challenges hinge on prior art and obviousness evaluations.
• Litigation costs can be substantial; strategic early dispute resolution may be advantageous.
• Patent outcomes significantly impact market exclusivity and generic entry timelines.

---

FAQs

1. What were the core allegations in Cephalon v. Slayback?
   Cephalon alleged that Slayback infringed its patents related to controlled-release oxycodone formulations.

2. How did the court rule on patent validity?
   The court upheld the patents' validity but found that Slayback’s products did not infringe the patents, leading to dismissal of infringement claims.

3. What is the significance of claim construction in this case?
   Claim construction clarified patent scope, which was crucial in determining non-infringement.

4. Can patent invalidity theories succeed in such litigation?
   Yes, if challenger proves prior art or obviousness, patents can be invalidated, as seen in various cases.

5. What are likely future considerations for patent holders after this case?
   Patent owners should ensure claims are robust, consider litigation strategies carefully, and monitor market entry timelines closely.

---

References

1. Court Records, District of Delaware, Case 1:17-cv-01154-CFC.
2. Patent documents: U.S. Patent Nos. 8,596,563 and 8,809,753.
3. Legal filings and public statements from the parties, 2017–2019.